ライフサイエンスコーパス: protooncogene

1 licate Nrf2 as both a tumor suppressor and a protooncogene.

2 to Elk-1 splice variant DeltaElk-1 and c-Fos protooncogene.

3 eceptor tyrosine kinase encoded by the c-Met protooncogene.

4 n hematopoietic stem cells and is a leukemia protooncogene.

5 of alpha-enolase in regulation of the c-myc protooncogene.

6 AMP might also include regulators of the Ras protooncogene.

7 lin-1 cellular gene is suppressed by the p53 protooncogene.

8 like 2 (GRHL2) transcription factor as novel protooncogene.

9 ed signaling appears to converge on the AP-1 protooncogene.

10 oligonucleotides targeted to the human c-myc protooncogene.

11 , and induction of the Stat5-regulated pim-1 protooncogene.

12 otein to activate transcription of the c-fos protooncogene.

13 early responsive genes, including the c-fos protooncogene.

14 ted domain (GRD) with the product of the ras protooncogene.

15 led homology to different regions of the FES protooncogene.

16 mutant tumors showed accumulation of the DEK protooncogene.

17 pathway of growth suppression and the bcl-2 protooncogene.

18 rtially inhibited by expression of the Bcl-2 protooncogene.

19 , including activating mutations in the KRAS protooncogene.

20 ned codon 61 (underlined) of the human N-ras protooncogene.

21 utagens that activate expression of cellular protooncogenes.

22 mors in C3H/He mice show upregulation of Int protooncogenes.

23 esis-i.e., extracellular matrix proteins and protooncogenes.

24 by an ordered program of turning off several protooncogenes.

25 hypothesis, cancer is caused by mutation of protooncogenes.

26 downregulating the activity of activated Ras protooncogenes.

27 Expression of the protooncogene A-myb is restricted to the developing CNS,

28 Mutations of the RET protooncogene (a growth factor receptor) occur in nearly

29 onin, neuron-specific enolase, and the c-met protooncogene (a hepatic growth factor/scatter factor re

30 Wnt-1 was first identified as a protooncogene activated by viral insertion in mouse mamm

31 cABL is a protooncogene, activated in a subset of human leukemias,

32 reast cancer cells and is a direct target of protooncogene ACTR/AIB1/SRC-3.

33 The protooncogenes Akt and c-myc each positively regulate ce

34 We identified the protooncogene and guanine nucleotide exchange factor Vav

35 atory elements that govern expression of the protooncogene and provide a new system for studying the

36 ectodomain of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/

37 ed to establish a relationship between c-ret protooncogene and some of the growth factors which are k

38 ar growth control genes, including the c-myc protooncogene and the gene encoding FAP-1 phosphatase.

39 asia type 2 (MEN2) have mutations in the RET protooncogene and virtually all of them will develop med

40 icularly interesting is the possible role of protooncogenes and angiogenic factors in the development

41 Translation initiation of several important protooncogenes and growth-regulators, such as Myc and FG

42 probably requires the activation of cellular protooncogenes and loss of tumor suppressor gene functio

43 the presence of dysplasia, and mutations in protooncogenes and tumor formation.

44 cond position of codon 61 of the human N-ras protooncogene, and was named the ras61 S-N1-BDO-(61,2) a

45 Because protooncogenes are conserved in evolution and are presum

46 rant expression in tumor cells, in which ras protooncogenes are frequently mutated.

47 , 61 (underlined), and 62 of the human N-ras protooncogene, are described.

48 Here, we identified the BCL6 protooncogene as a critical effector downstream of FoxO

49 tified Cbl, the protein product of the c-cbl protooncogene, as an early tyrosine kinase substrate upo

50 BV integrations to function as activators of protooncogenes, as well as agents of the loss of tumor s

51 he SRSR(61,2) adduct, derived from the N-ras protooncogene at and adjacent to the nucleotides encodin

52 virus (HCV) core protein regulates cellular protooncogenes at the transcriptional level; this observ

53 amically samples a large surface area of the protooncogene B-catenin.

54 The protooncogene Bcl-2 functions as a suppressor of apoptos

55 The protooncogene bcl-2 is known to be a potent regulator of

56 Expression of the human protooncogene bcl-2 protects neural cells from death ind

57 The protooncogene BCL-6 is also involved in TH2 differentiat

58 Bcr-Abl, the product of the protooncogene bcr-abl, is a constitutively active protei

59 oplasia related to insertional activation of protooncogenes by retroviral vectors have raised serious

60 The protooncogene c-abl encodes a nonreceptor tyrosine kinas

61 Cbl is the product of the protooncogene c-cbl and is involved in T cell antigen re

62 The protooncogene c-Cbl has recently emerged as an E3 ubiqui

63 TCF alone does not bind the SRE of the protooncogene c-fos, but requires the prior assembly of

64 actors activating transcription factor 3 and protooncogene c-fosDLCs could represent a promising adju

65 The protooncogene c-jun encodes the founding member of the a

66 Although the protooncogene c-Jun plays a critical role in cell prolif

67 ultures induces the receptor tyrosine kinase protooncogene c-kit and that high levels of c-Kit expres

68 he major recent finding of a mutation in the protooncogene c-kit which is unique to gastrointestinal

69 ng up on our previous novel finding that the protooncogene c-Maf of the basic leucine zipper family o

70 The protooncogene c-met encodes the tyrosine kinase receptor

71 Growth Factor (HGF) receptor, encoded by the protooncogene c-met, is overexpressed in many human tumo

72 Previous reports have suggested that the protooncogene c-myb participates in T cell development i

73 ) phase, whereas coexpression of p53 and the protooncogene c-myc induces apoptosis.

74 Here we show that the protooncogene c-Myc is an essential early regulator of n

75 nse oligodeoxynucleotides suggested that the protooncogene c-myc is obligatory for activation-induced

76 The protooncogene c-myc regulates cell growth, differentiati

77 gion, including translocations involving the protooncogene c-MYC, have been frequently reported in pe

78 ociated protein, to the kinase domain of the protooncogene c-ROS.

79 ropoietin regulates the transcription of the protooncogenes c-myc and c-myb by discrete protein kinas

80 receptor, myeloproliferative leukemia virus protooncogene (c-Mpl, or Mpl), controls HSC homeostasis

81 thway, to increase the expression of certain protooncogenes (c-fos, c-myc and c-jun) and growth facto

82 expression of immediate-early genes (IEGs), protooncogene, c-Fos, and zinc finger protein, Zif268, a

83 TNF-alpha induced expression of both early protooncogenes, c-fos and c-jun.

84 The mRNA levels of two growth-related protooncogenes, c-fos and c-myc, were up-regulated signi

85 To explore whether the protooncogenes, c-fos/c-jun, might be involved in regula

86 Deregulated expression of two other protooncogenes, c-myc and c-myb, also has been shown to

87 that transcriptional activation of the TCL1 protooncogene can cause malignant transformation of T ly

88 But there is no evidence that known mutated protooncogenes can transform human cells.

89 ein in oncogenesis and establishes SKP2 as a protooncogene causally involved in the pathogenesis of l

90 complex is the 120-kDa product of the c-cbl protooncogene (Cbl).

91 integration sites near or within established protooncogenes (Chd9, Slamf6, Tde1, Camk2b, and Ly6e), d

92 s orthologous to human 11q22, which contains protooncogenes cIAP1 (Birc2), cIAP2 (Birc3) and Yap1.

93 The HMGA1 protooncogene codes for two closely related isoform prot

94 uced c-src/tubulin association indicates the protooncogene complexes primarily, if not exclusively, w

95 Significantly, several protooncogenes contain DEF domains and are regulated by

96 dexamethasone treatment suggests that these protooncogenes could mediate the effect of glucocorticoi

97 esent in the 3' untranslated regions of many protooncogene, cytokine, and lymphokine messages target

98 st, an inducible activated form of the Raf-1 protooncogene (delta RAF-1:ER) was expressed in these ce

99 its PSC cell proliferation by repressing the protooncogene dmyc.

100 ell cycle regulation through binding the Akt protooncogene; dysfunction in either may account for the

101 amino acid substitutions vis-a-vis the c-src protooncogene-encoded product pp60c-src.

102 The human ECT2 protooncogene encodes a guanine nucleotide exchange fact

103 The c-myb protooncogene encodes a highly conserved 75-89-kDa trans

104 The c-rel protooncogene encodes a member of the Rel/nuclear factor

105 The c-fes protooncogene encodes a nonreceptor tyrosine kinase (Fes

106 The c-fes protooncogene encodes a nonreceptor tyrosine kinase (Fes

107 The Gfi-1 protooncogene encodes a nuclear zinc-finger protein that

108 The c-kit protooncogene encodes a receptor tyrosine kinase that is

109 e epithelial cell transforming gene 2 (ECT2) protooncogene encodes a Rho exchange factor, and regulat

110 The Akt protooncogene encodes a serine-threonine protein kinase

111 The c-ski protooncogene encodes a transcription factor that binds

112 The c-KIT protooncogene encodes KIT, a tyrosine kinase that is the

113 l translocations commonly activate the BCL-2 protooncogene, endowing B cells with a selective surviva

114 uences in the 5' untranslated regions of the protooncogenes erbB-2 and erbB-3.

115 17beta-Estradiol (E2) induces c-fos protooncogene expression in MCF-7 human breast cancer ce

116 processes as diverse as cell cycle control, protooncogene expression, cellular defense against HIV i

117 a gene-specific means of inhibiting specific protooncogene expression.

118 ooping and concomitant activation of the MYC protooncogene expression.

119 onsequence of combined HOXB4 and deregulated protooncogene expression.

120 otein shares extensive homology with the maf protooncogene family.

121 The cbl-b gene is a member of the cbl protooncogene family.

122 gets multiple transcriptional activators and protooncogenes for ubiquitin-mediated degradation.

123 anslation initiation factor eIF4E is a novel protooncogene found over expressed in most breast carcin

124 The Ki-ras protooncogene frequently is mutated in colorectal adenoc

125 The MYC protooncogene functions as a universal amplifier of tran

126 The RAS protooncogene has a central role in regulation of cell p

127 Overexpression of the MYC protooncogene has been implicated in the genesis of dive

128 Overexpression of the HER2/Neu protooncogene has been linked to the progression of brea

129 Tyrosine phosphorylation of the Cbl protooncogene has been shown to occur after engagement o

130 Although sporadic gain-of-function of protooncogenes has been successfully modeled in mice, ge

131 Although initiating mutations in the ret protooncogene have been found in familial and sporadic m

132 t specific protein subdomains within the Vav protooncogene have in the development of these two disti

133 that are conditionally deleted for the c-jun protooncogene in epidermis are born at expected frequenc

134 enic mice that conditionally express the MYC protooncogene in hematopoietic cells.

135 the protumorigenic stabilization of the MDM4 protooncogene in human HCC by way of a posttranscription

136 alpha stimulates the expression of the FRA-1 protooncogene in human pulmonary epithelial cells using

137 Expression of the Wnt-1 protooncogene in mammary glands of transgenic mice expan

138 nding protein that is homologous to a T cell protooncogene in three well-conserved domains.

139 ptor tyrosine kinase, is unusual among human protooncogenes in that its mutant alleles are implicated

140 hough originally described for their role as protooncogenes in the development of several types of hu

141 oblastoma Ras viral oncogene homolog (N-Ras) protooncogenes in the liver by way of hydrodynamic gene

142 s identified a remarkable number of putative protooncogenes in these lymphomas, which included loci t

143 ctivated protein kinase pathways and several protooncogenes, including c-myc and Pim-1.

144 tivities that activates transcription of key protooncogenes, including MYC We report that BRD4 phosph

145 rowth regulator dMyc, a homolog of the c-myc protooncogene, induces cell competition and leads to the

146 formation of these cells by translocation of protooncogenes into the immunoglobulin (Ig) loci.

147 The protein product of the c-cbl protooncogene is a 120-kD protein that is expressed in e

148 The deregulation of the c-myc protooncogene is a critical oncogenic event in the devel

149 The c-myc protooncogene is a key regulator of cell proliferation w

150 The Vav protooncogene is a multidomain protein involved in the r

151 The product of the c-abl protooncogene is a nonreceptor tyrosine kinase found in

152 The c-maf protooncogene is a T helper cell type 2 (Th2)-specific t

153 The MYC protooncogene is a transcription factor whose overexpres

154 h factor/scatter factor encoded by the c-met protooncogene is also expressed in limb muscle progenito

155 Aberrant overexpression of the c-rel protooncogene is associated with lymphoid malignancy, wh

156 The MYC protooncogene is associated with the pathogenesis of mos

157 The Vav protooncogene is expressed almost exclusively in hematop

158 The MYC protooncogene is frequently deregulated in human cancers

159 t has been hypothesized that gain of the MYC protooncogene is of central importance in trisomy 8, but

160 The product of Cbl protooncogene is one such regulator, which functions as

161 The c-myc protooncogene is overexpressed in a variety of human can

162 The TCL1 protooncogene is overexpressed in many mature B cell lym

163 The neu/erbB2 protooncogene is overexpressed in numerous human cancers

164 Here we show that induction of the MYC protooncogene is required for cell transformation by vIR

165 The c-Myb protooncogene is required for definitive hematopoiesis i

166 r transcriptional up-regulation of the c-fos protooncogene, is constitutively occupied by a protein c

167 ctor receptor (M-CSFR), encoded by the c-fms protooncogene, is overexpressed on microglia surrounding

168 e significant cytoplasmic levels of Bcl-2, a protooncogene known to prolong cellular viability and to

169 anscriptional activation) why known, mutated protooncogenes lack transforming function in human cells

170 Intracellular activated Notch (ICN) is a protooncogene linked to the transcription activation of

171 ranslocations involving antigen receptor and protooncogene loci, it is critical to understand the typ

172 Which protooncogene may have the dominant role in embryonic re

173 e identified the essential p53 inhibitor and protooncogene MDM2 as a putative target.

174 The implications of a protooncogene-mediated suppression of TSP expression are

175 n human breast cancer, overexpression of the protooncogene MET is strongly associated with poor progn

176 tiated tumorigenesis with a transgene of the protooncogene MET or by hydrodynamic transfection of MET

177 iquitously expressed protein, related to the protooncogene Myb, that is present at telomeres througho

178 The protooncogene MYC encodes the c-Myc transcription factor

179 The protooncogene MYC has been implicated in both the prolif

180 Hyperproliferation driven by the protooncogene MYC may lead to tumor suppressor p53 activ

181 The protooncogene MYC plays an important role in the regulat

182 The protooncogene MYC regulates a variety of cellular proces

183 We show that the protooncogene Myc regulates the expression of p48 throug

184 ary rodent fibroblasts when coexpressed with protooncogene myc.

185 ssed to mammary adenocarcinoma when a second protooncogene, MYC, was overexpressed, indicating that M

186 inhibition elicited by overexpression of the protooncogene MYCN.

187 Induction of a protooncogene, normally involved in mitogenic responses,

188 The human protooncogene Nup214 was first identified as a target fo

189 Activation of the c-abl protooncogene occurs during the generation of both the A

190 K/SAPK leads to the phosphorylation of c-JUN protooncogene on serines 63 and 73.

191 can cause tumors when they integrate near a protooncogene or tumor suppressor gene of the host.

192 The KIT protooncogene or, less frequently, platelet-derived grow

193 d tumors result in deregulated expression of protooncogenes or creation of chimeric proteins with tum

194 cancers involve either somatic activation of protooncogenes or inactivation of tumor-suppressor genes

195 The targeted repair of mutant protooncogenes or the inactivation of their gene product

196 ted by microinjecting MB targeted to the vav protooncogene, or control MB, into K562 human leukemia c

197 e proteins as certain cellular genes, termed protooncogenes, our data must also be relevant to the on

198 was required for upregulation of the T cell protooncogene p21.

199 link between the interleukin-2 receptor, the protooncogene PKB, and p70 S6 kinase.

200 The c-Myc protooncogene places a demand on glucose uptake to drive

201 Members of the myc family of nuclear protooncogenes play roles in cell proliferation, differe

202 The c-myc protooncogene plays a key role in the abnormal growth re

203 The c-myc protooncogene plays an important role in the abnormal gr

204 c-myb, a protooncogene prevalently expressed in the hematopoietic

205 The c-cbl protooncogene product (p120(cbl)) is a known substrate o

206 cells have been identified as the p120 c-Cbl protooncogene product and the p85 subunit of phosphatidy

207 The protooncogene product Cbl has emerged as a negative regu

208 The protooncogene product Cbl has emerged as a novel signal

209 The Cbl protooncogene product has emerged as a negative regulato

210 The Cbl protooncogene product has emerged as a novel negative re

211 nt of NB-4 human cells with IFN-gamma, c-cbl protooncogene product is rapidly phosphorylated on tyros

212 resent in activated T cell lysates as Cbl, a protooncogene product of unknown function which was foun

213 The Ser/Thr kinase Raf-1 is a protooncogene product that is a central component in man

214 arrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific

215 ntracellular substrates, including the 95-kD protooncogene product Vav.

216 ces rapid tyrosine phosphorylation of Cbl, a protooncogene product which has been implicated in intra

217 ation of cellular proteins, including Cbl, a protooncogene product whose function remains unclear.

218 phosphotyrosine-binding (PTB) domain of the protooncogene product, c-Cbl.

219 stinct signaling cascade involving the c-cbl protooncogene product, CrkL adapter, and small G protein

220 ic exposure elicited expression of the c-fos protooncogene product, FOS, in nucleus of the solitary t

221 ely high levels of autoantibodies to the DEK protooncogene product.

222 their interaction with several oncogene and protooncogene products.

223 The bcl-2 protooncogene promotes cell survival and protects agains

224 unodominant peptide, E75, from the HER-2/neu protooncogene protein recognized by CTL.

225 re the association of Smad3 with the nuclear protooncogene protein Ski in response to the activation

226 re the association of Smad3 with the nuclear protooncogene protein SnoN.

227 of most other 14-3-3 partners, including the protooncogene Raf, which nevertheless remain capable of

228 Mutations that activate the protooncogene ras, such as loss of Nf1, cooperate with i

229 Hepatocyte Growth Factor (HGF) and its protooncogene receptor c-Met regulate osteoclast functio

230 ified an interaction of GPX1 with the orphan protooncogene receptor tyrosine kinase ROS1.

231 novel putative targets identified, the c-fos protooncogene regulator ELK-1 was characterized as the f

232 Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain

233 , 61 (underlined), and 62 of the human N-ras protooncogene, results from trans opening of (1R,2S,3S,4

234 The receptor tyrosine kinase ret protooncogene (RET) is implicated in the pathogenesis of

235 To demonstrate this, we targeted the c-MYB protooncogene's mRNA in human leukemia cells with fully

236 e, microsatellite instability, and the B-Raf protooncogene, serine/threonine kinase (BRAF), mutation)

237 els of mRNA and protein encoded by the c-myc protooncogene set the balance between proliferation and

238 The data suggest that, although a number of protooncogenes share similar catalytic domains, c-ret pl

239 Protooncogene Ski was identified based on its ability to

240 ates microtubules in a manner similar to the protooncogene, specifically coimmunoprecipitates with c-

241 GBC are associated with mutation of several protooncogenes such as EGFR, ERBB2, Myc, and CCND1 along

242 le strains through insertional activation of protooncogenes, such as members of the wnt and fibroblas

243 ancer hypothesis holds that mutated cellular protooncogenes, such as point-mutated proto-ras, "play a

244 The regions encode a family of protooncogenes (TCL1, MTCP1, and TCL1b) of unknown funct

245 gene, and the receptor tyrosin kinase (RET) protooncogene that are associated with cystic fibrosis,

246 Our results identify UbcH10 as a prominent protooncogene that causes whole chromosome instability a

247 Evi1 is a myeloid-specific protooncogene that encodes 145 kDa and 88 kDa proteins v

248 ctor receptor (EGFR) is a well-characterized protooncogene that has been shown to promote tumor progr

249 Protein kinase Tpl2/Cot is encoded by a protooncogene that is cis-activated by retroviral insert

250 odes a Trithorax-related chromatin-modifying protooncogene that positively regulates Hox genes.

251 rough overexpression or mutation, is a major protooncogene that provides an attractive molecular targ

252 ificant decrease of mRNA level for the c-myc protooncogene that regulates telomerase.

253 also mediates the ubiquitination of another protooncogene, the non-receptor tyrosine kinase c-Src, a

254 s with unconstrained activation of the c-Met protooncogene to induce hepatocarcinogenesis via in vitr

255 threonine protein kinase encoded by the Tpl2 protooncogene transduces Toll-like and death receptor si

256 The protein product of this protooncogene, TrkA, is a receptor tyrosine kinase for n

257 hosphorylation of a substrate peptide by the protooncogene tyrosine kinase c-src.

258 gineered to overexpress the HER-2/neu/erbB-2 protooncogene under the control of a mammary-specific pr

259 )C(22)), bearing codon 12 of the human N-ras protooncogene (underlined), was determined.

260 C), encompassing codon 12 of the human n-ras protooncogene (underlined), were refined from 1H NMR dat

261 We show herein that the product of the protooncogene vav is constitutively Tyr-phosphorylated i

262 ll receptor ligation by interacting with the protooncogene Vav, which leads to subsequent tyrosine ph

263 several intracellular proteins including the protooncogene Vav1.

264 a single cDNA encoding a variant of the TrkA protooncogene was isolated.

265 , 61 (underlined), and 62 of the human N-ras protooncogene, was determined by NMR.

266 ns 60, 61(italic), and 62 of the human N-ras protooncogene, was determined.

267 , 61 (underlined), and 62 of the human N-ras protooncogene, was determined.

268 Mutations in codons 12 and 13 of the Ki-ras protooncogene were analyzed in baseline adenomas 0.5 cm

269 In addition, the mutated protooncogenes were amplified in HCV-associated lymphoma

270 piens, HSA) DNA probes for GLI, HST and INT2 protooncogenes were used to identify their homologous lo

271 , 61 (underlined), and 62 of the human n-ras protooncogene, were examined by 1H NMR.

272 , 61 (underlined), and 62 of the human N-ras protooncogene, were refined from (1)H NMR data.

273 c-myc is an important protooncogene whose misregulation is believed to causall

274 romosomal translocations juxtaposing the MYC protooncogene with regulatory sequences of immunoglobuli

275 The role of various receptor-like protooncogenes, with the emphasis on c-ros and c-ret, wa

276 Receptor-like protooncogenes, with tyrosine kinase catalytic domains,

277 ome this defect by ectopic expression of the protooncogene Wnt-1.